Literature DB >> 21364908

Large novel deletions detected in Chinese families with aniridia: correlation between genotype and phenotype.

Xiaohui Zhang1, Qingsheng Zhang, Yi Tong, Hanjun Dai, Xin Zhao, Fengge Bai, Liang Xu, Yang Li.   

Abstract

PURPOSE: To describe the clinical and genetic findings in two Chinese families with aniridia and other ocular abnormalities.
METHODS: Two unrelated families were examined clinically. After informed consent was obtained, genomic DNA was extracted from the venous blood of all participants. Mutation screening of all exons of the PAX6 (paired box gene 6) gene was performed by direct sequencing of PCR-amplified DNA fragments. Multiplex ligation-dependent probe amplification (MLPA) was performed to detect large deletions. Linkage analysis was used to validate the large deletions revealed by MLPA in all available family members.
RESULTS: Clinical examination and pedigree analysis revealed one four-generation family (85) and one three- generation family (86) with total aniridia, congenital cataracts, foveal hypoplasia, and glaucoma. No mutation in PAX6 was identified after PCR-sequencing. Through MLPA analysis, a large deletion including the whole PAX6 gene, DKFZp686k1684 (hypothetical LOC440034), and the RCN1 (reticulocalbin 1) gene was detected in family 85; a 3' deletion to the PAX6 gene including the ELP4 (elongator complex protein 4) and the DCDC1 (doublecortin domain containing 1) gene was identified in family 86.The two large deletions were confirmed with linkage analysis and the "loss of heterozygous" in the different PAX6 regions were co-segregated with the phenotype of the two families, respectively.
CONCLUSIONS: Patients with the PAX6 contiguous gene deletion, including the RCN1 gene, presented more severe vision impairments than those carrying the PAX6 3' deletion. Large deletions may account for several Chinese families and sporadic cases with aniridia and screening for these kinds of alterations should be included in aniridia patients' analyses.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21364908      PMCID: PMC3044699     

Source DB:  PubMed          Journal:  Mol Vis        ISSN: 1090-0535            Impact factor:   2.367


Introduction

Aniridia (AN; OMIM 106210) is a rare congenital disorder characterized by the complete or partial absence of the iris. The incidence of AN in the general population is about 1 in 64,000 to 96,000 [1]. Vision is usually impaired by other ocular abnormalities such as corneal opacification, cataract, glaucoma, fovea and optic nerve hypoplasia, and nystagmus [1]. About two-thirds of AN cases are families with an autosomal dominant mode of inheritance. In the remaining third no family history is found. The aniridia gene was first mapped on chromosome 11p13 by linkage analysis, and then isolated by positional cloning in 1991 [2]. The PAX6 (paired box gene 6) gene spans 22 kilobases and contains 14 exons, including an alternatively splicing exon5a. Therefore, there are two isoforms: PAX6 (−5a), comprising 422 amino acids, and PAX6 (+5a), comprising 436 amino acids [2,3]. PAX6 encodes a transcription factor that is involved in several development pathways and is expressed early in the development of the eye, numerous regions of the brain, and the pancreas. PAX6 contains an NH2-terminal paired domain, a homeodomain separated by a glycine-rich linker sequence, and a COOH-terminal proline-serine-threonine rich transregulatory domain [2,3]. Most aniridia cases are caused by intragenic mutations of PAX6, which include nonsense mutations, splicing mutations, frame-shifting insertions or deletions, in-frame insertions or deletions, missense mutations, and run-on mutations [2-7]. A small numbers of aniridia cases can be due to large chromosomal deletions or rearrangements [2,8]. Aniridia generally occurs in isolation or accompanied by other ocular malformations, but it occurs, more rarely, as part of the WAGR (Wilms’ tumor, aniridia, genitourinary abnormalities, and mental retardation) syndrome (OMIM 194072) [9]. WAGR is usually caused by deletions of chromosome 11p13, which include PAX6 and WT1 (Wilms tumor 1) [9]. As large deletions could not be identified by the routine PCR-sequencing mutation detection method, only a few isolated aniridia patients with the large deletions in the PAX6 region have been documented and the most of them are sporadic cases [2,8-18]. In this study, we describe the clinical findings in two Chinese families with two different large deletions in the region of PAX6.

Methods

Patients and DNA sample collection

This study was performed according to the tenets of the Declaration of Helsinki for research involving human subjects. This study was approved by the Beijing Tongren Hospital Joint Committee on Clinical Investigation, Beijing, China. After informed consents were obtained, participants underwent ophthalmologic examination including bilateral best corrected visual acuity using E decimal charts, slit-lamp biomicroscopy inspection of the anterior chamber, intraocular pressure (IOP) measurement by applanation tonometry (Goldmann), and fundus examination with a 66-diopter VOLK lens. Some patients underwent electroretinography (ERG) and A/B ultrasonic scan examination.

Mutation screening of PAX6

Peripheral blood was obtained by venipuncture and genomic DNA was extracted according to standard protocols. The 14 exons of PAX6 were amplified by polymerase chain reaction (PCR) from genomic DNA. Thirteen pairs of primers for PAX6 were used (Table 1), according to the article previously published [17]. For direct sequencing, PCR products were purified (Shenneng Bocai PCR purification kit; Shenneng, Shanghai, China). An automatic fluorescence DNA sequencer (ABI, Prism 373A; Perkin Elmer, Foster City, CA), used according to the manufacturer’s instructions, sequenced the purified PCR products in both forward and reverse directions. DNAssit, version 1.0 compared nucleotide sequences with the published DNA sequence of PAX6 (GenBank NM_001604.3).
Table 1

PAX6 PCR primers used in this study

PrimerForward (5'-3')Reverse (5'-3')Tm (°C)Product size (bp)
exon1
AGGGAACCGTGGCTCGGC
GGGTGAGGGAAGTGGCTGC
62
207
exon2
TTATCTCTCACTCTCCAGCC
GGAGACCTGTCTGAATATTGC
54
307
exon3
TCAGAGAGCCCATGGACGTAT
CTGTTTGTGGGTTTTGAGCC
58
193
exon4
AGTTCAGGCCTACCTGATGC
GTCGCGAGTCCCTGTGTC
58
201
exon5
CTCCCTCATCTTCCTCTTCC
GGGGTCCATAATTAGCATCG
58
327
exon6-7
GGGCTACAAATGTAATTTTAAGAAA
AGAGAGGGTGGGAGGAGGTA
56
509
exon8
GAGCTGAGATGGGTGACTG
GAGAGTAGGGGACAGGCAAA
58
300
exon9
AGACTACACCAGGCCCCTTT
TGAAGATGTGGCATTTACTTTGA
58
291
exon10
GGAACCAGTTTGATGCACAG
ACTCTGTACAAGCACCTCTGTCTC
58
243
exon11
GGGCTCGACGTAGACACAGT
GGAAACTGAGGGCAAGAGAA
56
300
exon12
CGGGCTCTGACTCTCACTCT
GCCACTCCTCACTTCTCTGG
60
220
exon13
GCTGTGGCTGTGTGATGTGT
AGGAGATTCTGTTTGGGTA
52
281
exon14TCCATGTCTGTTTCTCAAAGGTCAACTGTTGTGTCCCCATAG56219

Multiplex ligation-dependent probe amplification (MLPA analysis)

MLPA was performed with SALSA MLPA Kits P219 (Amsterdam, the Netherlands) according to the manufacturer’s instructions. In brief, 100 ng DNA was denatured and hybridized with the SALSA probe mix overnight at 60 °C. The samples with ligase 65 were incubated for 15 min at 54 °C, after which PCR amplification was performed with the specific SALSA FAM PCR primers. The PCR products were separated by capillary electrophoresis on an automatic fluorescence DNA sequencer (ABI, Prism 373A; Perkin Elmer). Data analysis was performed by exporting the peak areas to a Microsoft Excel (Microsoft Corporation, Redmond, WA) file. Each peak was first normalized as described elsewhere [17] and the normalized peak was then divided by the mean of that peak in the control samples. The ratios outside the range of 0.7–1.3 times the control peak area were considered abnormal, with those below 0.7 representing deletions and those above 1.3 representing duplications. For each MLPA analysis, several normal controls were included and the standard deviation for the normal samples was usually less than 10% of the mean. Each result was confirmed by two independent tests.

Linkage analysis

To validate the large deletions detected by MLPA, genotyping for families 85 and 86 was performed with the following 8 microsatellite markers: D11S905, D11S1776, GDB.250586, PAX6.CA/GT, D11S995, D11S2001, D11S4156, and D11S904. The fine mapping primer sequences were obtained from the GDB (Human Genome Database). The positions of these markers related to WT1, RCN1 (reticulocalbin 1), DKFZ p686k1684 (hypothetical LOC440034), PAX6, ELP4 (elongator complex protein 4), and DCDC1 (doublecortin domain containing 1) are shown in Figure 1.
Figure 1

Schematic representation of WT1/ RCN1/ DKFZ p686k1684/PAX6/ ELP4/ DCDC1 on chromosome 11p13 and the relative positions of the microsatellite markers and single nucleotide polymorphism (SNP) used in linkage and real-time quantitative PCR analysis. D presents DKFZ p686k1684. Brown arrows below the each gene indicated the transcription direction for each gene. The region between the two blue vertical lines presents the deleted region (407 Kb) of family 85, the region between the two purple vertical lines presents the deleted region (527 Kb) of family 86.

Schematic representation of WT1/ RCN1/ DKFZ p686k1684/PAX6/ ELP4/ DCDC1 on chromosome 11p13 and the relative positions of the microsatellite markers and single nucleotide polymorphism (SNP) used in linkage and real-time quantitative PCR analysis. D presents DKFZ p686k1684. Brown arrows below the each gene indicated the transcription direction for each gene. The region between the two blue vertical lines presents the deleted region (407 Kb) of family 85, the region between the two purple vertical lines presents the deleted region (527 Kb) of family 86.

Real-Time Quantitative PCR analysis

To define the relative exact break point of the deletions, real-time quantitative PCR was performed in the affected members of the two families round the three regions (3′ to RCN1, 3′ to PAX6, and near the D11S4156 locus). Real-time quantitative PCR reactions were performed on the Rotor-Gene 6000 (Corbett Research, Mortlake, NSW, Australia) in a final volume of 10 μl, containing 300 nM primers and 1 μl (100 ng) genomic DNA, using the Eva green PCR Master Mix (Bio-Rad Laboratories, Hercules, CA). The primers in the analysis are shown in Table 2. Each assay was done in triplicate. The relative quantitation (RQ) of target gene was accomplished using RQ manager software (Bio Rad systems) and was calculated using the 2-ddCt method [19]. All experimental samples were normalized using human GAPDH as an internal control. The significance of the difference with a reference experiment was calculated with Student’s t-test.
Table 2

Primers sequences and the physical position used in real-time quantitative PCR and the results of MLPA and real-time PCR.

 
 
 
Family 85
Family 86
Gene/SNPPhysical positionPrimer sequences (5′-3′)MLPARQ result*MLPARQ result*
rs11031332
31235538
Fwd: CATTAGATTCATGTGGCTTGTTG
 


1.17
 
 
Rev: AATCCGATTCCTCGATTTGT
 
 
 
 
rs1929020
31237204
Fwd: TGACTGGTGCTACTGCCAAC
 
 
 
0.49
 
 
Rev: CTCCCGAATAGCGTGGATTA
 
 
 
 
DCDC1
31240747–31347897
 
-
 
+
 
ELP4
31487873–31761905
 
-
 
+
 
rs35674517
31763272–31763273
Fwd: TTCTTCCCCATTTTCTTTTCAA
 
1.18
 
 
 
 
Rev: TTCAGAATGTTCATAATGCTTTCAA
 
 
 
 
rs608293
31764856
Fwd: GAATATTTTTCCCCCAAAGC
 
0.44
 
1.07
 
 
Rev: TGAGAGGCCCAGAGTAAAAAGA
 
 
 
 
PAX6
31762916–31796085
 
+
 
-
 
DKFZp686K1684
31794690–31865163
 
+
 
-
 
RCN1
32074656–32083376
 
+
 
-
 
SHGC-143238
32102437–32102880
Fwd: TCCTCCCCTTGAGTCACTTACAT
 
0.5
 
 
 
 
Rev: TTACTTGCCAAAACACACTCCCT
 
 
 
 
rs7104670
32155485
Fwd: GTTACCACATTCGCAAAGCA
 
0.46
 
 
 
 
Rev: CAGACAAACACATTGACAGTCCT
 
 
 
 
rs12577592
32165037
Fwd: CCTTGCTCCTTTCAGTCCAG
 
0.35
 
 
 
 
Rev: ACCCTGAGTGTGTGTCATGC
 
 
 
 
rs4244480
32172819
Fwd: ACTTATCCCGCCCTTGTGTT
 
0.41
 
 
 
 
Rev: CACCAGGTTGTTTTGGGACT
 
 
 
 
rs72320219
32173790–32173791
Fwd: AGGAAAATCGCTTGAACCTG
 
1.08
 
 
 
 
Rev: GGGGTGGTTGTGAGGACTAA
 
 
 
 
GAPDH
6516714–6517797
Fwd: ACCCAGAAGACTGTGGATGG
 
 
 
 
  Rev: TTCTAGACGGCAGGTCAGGT    

Abbreviations: MLPA, Multiplex ligation-dependent probe amplification; RQ, relative quantity; +, deletion ; -, no deletion; *mean value of three times; Fwd, forward; Rev, reverse.

Abbreviations: MLPA, Multiplex ligation-dependent probe amplification; RQ, relative quantity; +, deletion ; -, no deletion; *mean value of three times; Fwd, forward; Rev, reverse.

Results

Clinical findings

We have identified one four-generation family (#85) and one three- generation family (#86) with aniridia. The inheritance pattern in the families was autosomal dominant (Figure 2). After clinical examinations and a review of hospital records, 11 individuals in family 85 were found to have aniridia. All patients presented bilateral complete absence of iris, severe congenital nystagmus, and congenital cataracts (Figure 3A,C). Foveal hypoplasia was observed in all fourth-generation patients except (IV-6; Figure 3D). The ERG of patient IV-7 showed slight cone cell dysfunction. The proband (III-4), her father, and her brother presented high intraocular pressure (IOP) and late stage glaucoma changes in the optic disc (Figure 3B). Due to the progressive density of the lens opacification, the fovea of patients in the second and third- generation and patient IV-6 could not be observed clearly. In family 86, five patients were identified and all patients had bilateral complete absence of iris and congenital cataracts (Figure 3E,G). Neither mental retardation nor other general abnormalities was observed or documented in all patients from the two families. Their detailed clinical features are summarized in Table 3.
Figure 2

Family structure and haplotype analysis of two Chinese families with aniridia. Pedigree and haplotype analysis of family 85 and 86 with aniridia showed “loss of heterozygous” segregation with the microsatellite marker PAX6.CA/GT (family 85), D11S995, and D11S2001 (family 86), respectively. All markers are on chromosome 11, listed in descending order from the centromeric end. Squares indicate males; circles indicate females; slashed symbols indicate deceased; solid symbols indicate affected; open symbols indicate unaffected.

Figure 3

Ophthalmological findings in patients from the two families. A: Photograph of anterior segment of patient III-4 of 85 with complete absence of iris and the progressing dense congenital cataract. B: Fundus images of patient III-4 showed late-stage glaucomatous cupping of the optic disc. C: Complete hypoplasia of the iris and congenital cataract were observed in patient IV-7 of family 85. D: Fundus images of patient IV-7 showing foveal hypoplasia. E: Photograph of anterior segment of patient II-4 of family 86 with complete absence of iris and congenital cataract. F: Fundus image of patient II-4 showing a tessellated appearance. G: Photograph of the anterior segment of patient III-3 of family 86 with complete absence of iris and mild cataract. H: Fundus image of patient III-3 showing a normal foveal reflex.

Table 3

The clinical features of patients in the two Chinese families.

Family numberPatient numberGender/Age yearBest corrected vision (OD/OS)IOPNystagmusAniridiaCongenital cataractGlaucomaFoveal hypoplasia
85
II-1
M/64
NLP
NA
S
C
YES
Late stage
NA
 
III-1
M/43
NLP
NA
S
C
YES
Late stage
NA
 
III-4
F/39
0.02/0.02
28/25
S
C
YES
Late stage
NA
 
IV-1
F/11
0.05/0.05
NA
S
C
YES
NO
YES
 
IV-2
M/7
NA
NA
S
C
YES
NO
YES
 
IV-3
M/6
NA
NA
S
C
YES
NO
YES
 
IV-4
M/5
NA
NA
S
C
YES
NO
YES
 
IV-5
M/3
NA
NA
S
C
YES
NO
NA
 
IV-6
M/18
0.1/0.1
NA
S
C
YES
NO
NA
 
IV-7
M/7
0.1/0.1
17/25
S
C
YES
NO
YES
86
I-1
M/71
0.2/0.4
NA
NO
C
YES
NO
NO
 
II-1
F/39
0.4/0.4
13/14
NO
C
YES
NO
NO
 
II-4
F/37
0.2/0.02*
16/11
NO
C
YES
NO
NO
 
III-2
F/9
0.4/0.6
19/18
NO
C
YES
NO
NO
 III-3M/70.8/0.610/12NOCYESNONO

Abbreviations: M, male; F, female; BCVA, best-correct visual acuity; OD, right eye; OS, left eye; NLP, no light peception; IOP, introocular pressure; NA, unavailable; S, sever; C, complete; *cornea of left eye was opacified due to the complication of implantation of iris diaphragm intraocular lens.

Family structure and haplotype analysis of two Chinese families with aniridia. Pedigree and haplotype analysis of family 85 and 86 with aniridia showed “loss of heterozygous” segregation with the microsatellite marker PAX6.CA/GT (family 85), D11S995, and D11S2001 (family 86), respectively. All markers are on chromosome 11, listed in descending order from the centromeric end. Squares indicate males; circles indicate females; slashed symbols indicate deceased; solid symbols indicate affected; open symbols indicate unaffected. Ophthalmological findings in patients from the two families. A: Photograph of anterior segment of patient III-4 of 85 with complete absence of iris and the progressing dense congenital cataract. B: Fundus images of patient III-4 showed late-stage glaucomatous cupping of the optic disc. C: Complete hypoplasia of the iris and congenital cataract were observed in patient IV-7 of family 85. D: Fundus images of patient IV-7 showing foveal hypoplasia. E: Photograph of anterior segment of patient II-4 of family 86 with complete absence of iris and congenital cataract. F: Fundus image of patient II-4 showing a tessellated appearance. G: Photograph of the anterior segment of patient III-3 of family 86 with complete absence of iris and mild cataract. H: Fundus image of patient III-3 showing a normal foveal reflex. Abbreviations: M, male; F, female; BCVA, best-correct visual acuity; OD, right eye; OS, left eye; NLP, no light peception; IOP, introocular pressure; NA, unavailable; S, sever; C, complete; *cornea of left eye was opacified due to the complication of implantation of iris diaphragm intraocular lens.

Mutation analysis

By the direct sequencing of 14 exons of PAX6, no mutation was detected in the two families.

MLPA Results

Using the MLPA Kits P219, two different deletions were detected in the two families (Figure 4). In family 85, a deletion of the whole PAX6 gene, the DKFZ p686k1684 gene, and the RCN1 gene was found; in family 86, a deletion of the ELP4 gene and the DCDC1 gene, which is located in the 3′ region of the PAX6 gene, was identified.
Figure 4

The normalized MLPA results of the probands of the two families. A: The normalized MLPA result of III-4 of family 85. B: The result of II-4 of family 86. The height of the columns represents of the dosage of the respective segments in the genomic DNA with two alleles. The light blue columns represent chromosome 11p13 specific probes. The orange columns represent the deleted probes. The dark blue columns represent the control probes. The allele dosage of the deleted probes was found in the range of about 0.5–0.7 of normal control, which corresponds to one allele.

The normalized MLPA results of the probands of the two families. A: The normalized MLPA result of III-4 of family 85. B: The result of II-4 of family 86. The height of the columns represents of the dosage of the respective segments in the genomic DNA with two alleles. The light blue columns represent chromosome 11p13 specific probes. The orange columns represent the deleted probes. The dark blue columns represent the control probes. The allele dosage of the deleted probes was found in the range of about 0.5–0.7 of normal control, which corresponds to one allele.

Genotyping Results

The two families were genotyped with several STRP markers located around PAX6 in the chromosome 11p13 region. The linkage analysis results were highly informative for the two families. For family 85, all patients display “loss of heterozygosis” at marker PAX6 CA/GT, which is located inside the PAX6 gene. All patients in family 86 show “loss of heterozygosis” at markers D11S995 and D11S2001, which is closed to ELP4 and DCDC1 (Figure 2).

Real-Time Quantitative PCR analysis results

This study set up a real-time quantitative PCR assay to define the relative breakpoint of the deletions. GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used to normalize PAX6 values. Assay for exon 8 of PAX6 were set up by using the patients in family 85 with the PAX6 deletion. The amplification plots are shown in Figure 5A,B, and the patient had about a half RQ value with respect to the normal control Figure 5C. Thus this study used this assay to analyze several single nucleotide polymorphisms (SNPs) around RCN1, PAX6, ELP4, and DCN1. The results were summarized in Table2. The relative exact breakpoints for the two families were showed in Figure 1.
Figure 5

Analysis of deletions in the PAX6 gene region by real-time quantitative PCR. A: Fluorescence amplification plots of the real-time quantitative PCR for exon 8 of the PAX6 gene, detected deletion by MLPA. B: Fluorescence amplification plots of the real-time PCR for rs7104670. Arrows in A and B indicated triplicate signals obtained for a control subject (Normal) and the patient III-1 of family 85 (Patient). C: Histogram indicated the relative quantity (RQ) between the exon8 of PAX6 or rs7104670 and GAPDH values. Bars represent mean values±standard deviations for the triplicate values.

Analysis of deletions in the PAX6 gene region by real-time quantitative PCR. A: Fluorescence amplification plots of the real-time quantitative PCR for exon 8 of the PAX6 gene, detected deletion by MLPA. B: Fluorescence amplification plots of the real-time PCR for rs7104670. Arrows in A and B indicated triplicate signals obtained for a control subject (Normal) and the patient III-1 of family 85 (Patient). C: Histogram indicated the relative quantity (RQ) between the exon8 of PAX6 or rs7104670 and GAPDH values. Bars represent mean values±standard deviations for the triplicate values.

Discussion

In this study, we described two Chinese families with aniridia and other ocular abnormalities. Using MLPA, a large deletion, including PAX6, DKFZ p686k1684, and RCN1, was identified in family 85; a deletion of ELP4 and DCDC1, leaving PAX6 intact, was found in family 86. The two deletions were co- segregated with the phenotype in the families, respectively. Until now, almost 300 intragenic mutations of PAX6 have been documented in the PAX6 allelic variation database [2-7]. Most of the intragenic mutations lead to premature protein truncation, which is likely to be acted on by nonsense-mediated decay (NMD). By reviewing the literature on genotype-phenotype correlation studies, the mutations that introduce premature terminated codons (PTCs) are consistently associated with aniridia or closely related phenotypes [6,7]. The patient carrying the complete deletion of PAX6, observed by Vincent et al. [15], did not present distinctive or more severe clinical manifestations than those associated with nonsense mutations. However, more severe bilateral visual impairment was observed in all the patients of family 85. The proband’s father and brother totally lost their sight at the age of 40 due to glaucoma. Several patients showed foveal hypoplasia. The large deletion detected in family 85 was novel and contained not only the complete PAX6 gene but also DKFZ p686k1684 and RCN1, which are located about 300 kb upstream of PAX6. RCN1 (reticulocalbin 1), resident in the endoplasmic reticulum, is a Ca2+ binding protein that participates in the secretory pathway and is expressed in the eye [20].Linkage between Pax6 and Rcn1 has been conserved in mice, humans, and fish [21]. Pax6 was originally isolated in the mouse and mutations in the gene are responsible for the small eye phenotypes. The mouse small eye phenotype had already been suggested through homology mapping to be the mouse counterpart of human aniridia [22]. Recently, Favel et al. [21] observed that the mouse, carrying a heterozygous Pax6 and Rcn1 contiguous deletion, presented an extreme microphthalmia phenotype. They inferred that Rcn1 might directly or indirectly contribute to the eye phenotype in Pax6 contiguous gene deletions. The severe visual impairment observed in family 85 seemed to be consistent with the phenotypes found in the mouse described by Favel et al. [21]. DKFZ p686k1684, located between PAX6 and RCN1, is a non-coding RNA with its function unclear[23]. The 3′ deletion identified in family 86 contained ELP4 and DCD4, which are located downstream of PAX6. The deletions in this region, which contains 3′ regulatory elements for PAX6, were documented in several earlier studies [12-18]. Most patients harboring the 3′ deletions had only aniridia and other ocular abnormalities, which is similar to the phenotype observed in most nonsense mutations patients. The patients in family 86 showed mild vision impairments due to aniridia and congenital cataracts. Davis et al. [18] described a patient carrying a 1.3 Mb deletion, including several additional genes expressed in the brain, who also presented with autism and mental retardation. In this study, the aniridia in both families was caused by large deletions in the PAX6 region. In general, patients with PAX6 contiguous deletion, including RCN1, may have relatively severe phenotypes. Large deletions may account for several Chinese families and sporadic cases with aniridia and screening for these kinds of alterations should be included in the aniridia patient’s analysis.
  23 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Population-based risk estimates of Wilms tumor in sporadic aniridia. A comprehensive mutation screening procedure of PAX6 identifies 80% of mutations in aniridia.

Authors:  K Grønskov; J H Olsen; A Sand; W Pedersen; N Carlsen; A M Bak Jylling; T Lyngbye; K Brøndum-Nielsen; T Rosenberg
Journal:  Hum Genet       Date:  2001-07       Impact factor: 4.132

3.  Mutation in the PAX6 gene in twenty patients with aniridia.

Authors:  L Y Chao; V Huff; L C Strong; G F Saunders
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

4.  Positional cloning and characterization of a paired box- and homeobox-containing gene from the aniridia region.

Authors:  C C Ton; H Hirvonen; H Miwa; M M Weil; P Monaghan; T Jordan; V van Heyningen; N D Hastie; H Meijers-Heijboer; M Drechsler
Journal:  Cell       Date:  1991-12-20       Impact factor: 41.582

5.  Pax: a murine multigene family of paired box-containing genes.

Authors:  C Walther; J L Guenet; D Simon; U Deutsch; B Jostes; M D Goulding; D Plachov; R Balling; P Gruss
Journal:  Genomics       Date:  1991-10       Impact factor: 5.736

6.  Molecular analysis of chromosome 11 deletions in aniridia-Wilms tumor syndrome.

Authors:  V van Heyningen; P A Boyd; A Seawright; J M Fletcher; J A Fantes; K E Buckton; G Spowart; D J Porteous; R E Hill; M S Newton
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

7.  Genomic structure, evolutionary conservation and aniridia mutations in the human PAX6 gene.

Authors:  T Glaser; D S Walton; R L Maas
Journal:  Nat Genet       Date:  1992-11       Impact factor: 38.330

8.  Analysis of Pax6 contiguous gene deletions in the mouse, Mus musculus, identifies regions distinct from Pax6 responsible for extreme small-eye and belly-spotting phenotypes.

Authors:  Jack Favor; Alan Bradley; Nathalie Conte; Dirk Janik; Walter Pretsch; Peter Reitmeir; Michael Rosemann; Wolfgang Schmahl; Johannes Wienberg; Irmgard Zaus
Journal:  Genetics       Date:  2009-05-27       Impact factor: 4.562

9.  Screening for PAX6 gene mutations is consistent with haploinsufficiency as the main mechanism leading to various ocular defects.

Authors:  Marie-Claire Vincent; Anne-Laure Pujo; David Olivier; Patrick Calvas
Journal:  Eur J Hum Genet       Date:  2003-02       Impact factor: 4.246

10.  Frequent chromosome aberrations revealed by molecular cytogenetic studies in patients with aniridia.

Authors:  John A Crolla; Veronica van Heyningen
Journal:  Am J Hum Genet       Date:  2002-10-17       Impact factor: 11.025

View more
  17 in total

1.  Crystal structure of elongator subcomplex Elp4-6.

Authors:  Zhijie Lin; Weijing Zhao; Wentao Diao; Xingqiao Xie; Zheng Wang; Jinxiu Zhang; Yuequan Shen; Jiafu Long
Journal:  J Biol Chem       Date:  2012-05-02       Impact factor: 5.157

Review 2.  Genetics of anterior segment dysgenesis disorders.

Authors:  Linda M Reis; Elena V Semina
Journal:  Curr Opin Ophthalmol       Date:  2011-09       Impact factor: 3.761

Review 3.  Aniridia due to a novel microdeletion affecting PAX6 regulatory enhancers: case report and review of the literature.

Authors:  Andreas Syrimis; Nayia Nicolaou; Angelos Alexandrou; Ioannis Papaevripidou; Michael Nicolaou; Eleni Loukianou; Violetta Christophidou-Anastasiadou; Stavros Malas; Carolina Sismani; George A Tanteles
Journal:  J Genet       Date:  2018-06       Impact factor: 1.166

Review 4.  Screening, genetics, risk factors, and treatment of neonatal cataracts.

Authors:  Jinyu Li; Chun-Hong Xia; Eddie Wang; Ke Yao; Xiaohua Gong
Journal:  Birth Defects Res       Date:  2017-05-22       Impact factor: 2.661

5.  PAX6 analysis of one family and one sporadic patient from southern China with classic aniridia.

Authors:  Ying Lin; Xialin Liu; Xuanwei Liang; Baoxin Li; Shuhong Jiang; Shaobi Ye; Huiqin Yang; Bingsheng Lou; Yizhi Liu
Journal:  Mol Vis       Date:  2011-11-26       Impact factor: 2.367

6.  A novel PAX6 deletion in a Chinese family with congenital aniridia.

Authors:  Jian Huan Chen; Weitao Lin; Guoying Sun; Chukai Huang; Yuqiang Huang; Haoyu Chen; Chi Pui Pang; Mingzhi Zhang
Journal:  Mol Vis       Date:  2012-04-21       Impact factor: 2.367

7.  Mutation analysis of PAX6 in inherited and sporadic aniridia from northeastern China.

Authors:  Yang Kang; Ying Lin; Xue Li; Qiong Wu; Lei Huang; Qingjun Li; Qi Hu
Journal:  Mol Vis       Date:  2012-06-27       Impact factor: 2.367

8.  Mutation analysis of paired box 6 gene in inherited aniridia in northern China.

Authors:  Peng Chen; Xinjie Zang; Dapeng Sun; Ye Wang; Yao Wang; Xiaowen Zhao; Mohan Zhang; Lixin Xie
Journal:  Mol Vis       Date:  2013-05-30       Impact factor: 2.367

9.  11p13 deletions can be more frequent than the PAX6 gene point mutations in Polish patients with aniridia.

Authors:  Anna Wawrocka; Agata Sikora; Lukasz Kuszel; Maciej R Krawczynski
Journal:  J Appl Genet       Date:  2013-06-13       Impact factor: 3.240

10.  A large novel deletion downstream of PAX6 gene in a Chinese family with ocular coloboma.

Authors:  Hong Guo; Limeng Dai; Yanming Huang; Qiong Liao; Yun Bai
Journal:  PLoS One       Date:  2013-12-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.